BioCentury | Nov 3, 2018
Product Development

New partners for NASH

...include: NGM’s NGM282, an engineered form of fibroblast growth factor 19 (FGF19) in Phase II; Galmed Pharmaceuticals Ltd.’s...
...plc (NYSE:AGN), Dublin, Ireland American Association for the Study of Liver Diseases (AASLD), Alexandria, Va. Galmed Pharmaceuticals Ltd....
...acid) cenicriviroc (tbr-652, TAK-652) elafibranor (GFT505) IMM-124E, imm124-e LJN452 MB07811, VK2809 MGL-3196, VIA-3196, 3196 NGM282 NGM313 Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) selonsertib (GS-4997) Allergan plc Galmed Pharmaceuticals Ltd. Genfit...
BioCentury | Jun 22, 2018
Financial News

Galmed raises $75M follow-on

...see "After NASH Readout, Galmed Looks to Phase III" ). Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Tel Aviv, Israel Alicia Parker Galmed Pharmaceuticals Ltd....
BioCentury | Jun 20, 2018
Financial News

Galmed raises $75M follow-on

...Looks to Phase III" ). Galmed lost $1.48 to $14.21 Wednesday. Alicia Parker Aramchol (arachidyl amino cholanoic acid) Galmed Pharmaceuticals Ltd....
BioCentury | Jun 14, 2018
Clinical News

After NASH readout, Galmed looks to Phase III

...to treat HIV-associated lipodystrophy and non-alcoholic fatty liver disease (NAFLD) (see BioCentury, Feb. 16) . Galmed Pharmaceuticals Ltd....
...of fibrosis at week 52 Status: Phase IIb data Milestone: NA Paul Bonanos Aramchol (arachidyl amino cholanoic acid) Galmed Pharmaceuticals Ltd. Stearoyl-CoA...
BioCentury | Jun 12, 2018
Clinical News

After NASH readout, Galmed looks to Phase III

...Tuesday's stock move pushed Galmed's market cap above $250 million. Paul Bonanos Aramchol (arachidyl amino cholanoic acid) Galmed Pharmaceuticals Ltd. Stearoyl-CoA...
BioCentury | Feb 16, 2018
Clinical News

Galmed's Aramchol misses in Phase IIa for HIV-associated NAFLD

...expected next quarter. The product is a synthetic conjugate of cholic acid and arachidic acid. Galmed Pharmaceuticals Ltd....
...AST) levels Status: Phase IIa data Milestone: Phase IIb data (2Q18) Jaime De Leon arachidyl amino cholanoic acid Aramchol Galmed Pharmaceuticals Ltd. Stearoyl-CoA...
BioCentury | Feb 14, 2018
Clinical News

Galmed falls on Phase IIa HIV-associated NAFLD miss

...product is a synthetic conjugate of cholic acid and arachidic acid. Jaime De Leon arachidyl amino cholanoic acid Aramchol Galmed Pharmaceuticals Ltd. Stearoyl-CoA...
BioCentury | Oct 3, 2016
Financial News

Galmed Pharmaceuticals completes private placement

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Tel Aviv, Israel Business: Hepatic, Gastrointestinal Date completed: 2016-09-29 Type: Private placement Raised: $4.8 million Shares: 933,160 Price: $5.11 Shares after offering: 12 million Placement agent: Cantor Fitzgerald Note: The shares...
BioCentury | Sep 9, 2016
Company News

Management tracks

...He was VP of global medical sciences at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Liver disease company Galmed Pharmaceuticals Ltd....
BioCentury | Mar 7, 2016
Clinical News

Aramchol arachidyl amino cholanoic acid: Phase IIa started

...once daily for 12 weeks in up to 50 patients with HIV-associated lipodystrophy and NAFLD. Galmed Pharmaceuticals Ltd....
Items per page:
1 - 10 of 32
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

...include: NGM’s NGM282, an engineered form of fibroblast growth factor 19 (FGF19) in Phase II; Galmed Pharmaceuticals Ltd.’s...
...plc (NYSE:AGN), Dublin, Ireland American Association for the Study of Liver Diseases (AASLD), Alexandria, Va. Galmed Pharmaceuticals Ltd....
...acid) cenicriviroc (tbr-652, TAK-652) elafibranor (GFT505) IMM-124E, imm124-e LJN452 MB07811, VK2809 MGL-3196, VIA-3196, 3196 NGM282 NGM313 Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) selonsertib (GS-4997) Allergan plc Galmed Pharmaceuticals Ltd. Genfit...
BioCentury | Jun 22, 2018
Financial News

Galmed raises $75M follow-on

...see "After NASH Readout, Galmed Looks to Phase III" ). Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Tel Aviv, Israel Alicia Parker Galmed Pharmaceuticals Ltd....
BioCentury | Jun 20, 2018
Financial News

Galmed raises $75M follow-on

...Looks to Phase III" ). Galmed lost $1.48 to $14.21 Wednesday. Alicia Parker Aramchol (arachidyl amino cholanoic acid) Galmed Pharmaceuticals Ltd....
BioCentury | Jun 14, 2018
Clinical News

After NASH readout, Galmed looks to Phase III

...to treat HIV-associated lipodystrophy and non-alcoholic fatty liver disease (NAFLD) (see BioCentury, Feb. 16) . Galmed Pharmaceuticals Ltd....
...of fibrosis at week 52 Status: Phase IIb data Milestone: NA Paul Bonanos Aramchol (arachidyl amino cholanoic acid) Galmed Pharmaceuticals Ltd. Stearoyl-CoA...
BioCentury | Jun 12, 2018
Clinical News

After NASH readout, Galmed looks to Phase III

...Tuesday's stock move pushed Galmed's market cap above $250 million. Paul Bonanos Aramchol (arachidyl amino cholanoic acid) Galmed Pharmaceuticals Ltd. Stearoyl-CoA...
BioCentury | Feb 16, 2018
Clinical News

Galmed's Aramchol misses in Phase IIa for HIV-associated NAFLD

...expected next quarter. The product is a synthetic conjugate of cholic acid and arachidic acid. Galmed Pharmaceuticals Ltd....
...AST) levels Status: Phase IIa data Milestone: Phase IIb data (2Q18) Jaime De Leon arachidyl amino cholanoic acid Aramchol Galmed Pharmaceuticals Ltd. Stearoyl-CoA...
BioCentury | Feb 14, 2018
Clinical News

Galmed falls on Phase IIa HIV-associated NAFLD miss

...product is a synthetic conjugate of cholic acid and arachidic acid. Jaime De Leon arachidyl amino cholanoic acid Aramchol Galmed Pharmaceuticals Ltd. Stearoyl-CoA...
BioCentury | Oct 3, 2016
Financial News

Galmed Pharmaceuticals completes private placement

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Tel Aviv, Israel Business: Hepatic, Gastrointestinal Date completed: 2016-09-29 Type: Private placement Raised: $4.8 million Shares: 933,160 Price: $5.11 Shares after offering: 12 million Placement agent: Cantor Fitzgerald Note: The shares...
BioCentury | Sep 9, 2016
Company News

Management tracks

...He was VP of global medical sciences at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Liver disease company Galmed Pharmaceuticals Ltd....
BioCentury | Mar 7, 2016
Clinical News

Aramchol arachidyl amino cholanoic acid: Phase IIa started

...once daily for 12 weeks in up to 50 patients with HIV-associated lipodystrophy and NAFLD. Galmed Pharmaceuticals Ltd....
Items per page:
1 - 10 of 32